Gross Profit Analysis: Comparing Viatris Inc. and Bausch Health Companies Inc.

Viatris vs. Bausch: A Decade of Gross Profit Trends

__timestampBausch Health Companies Inc.Viatris Inc.
Wednesday, January 1, 201460089000003669400000
Thursday, January 1, 201578538000004382200000
Friday, January 1, 201670630000004998500000
Sunday, January 1, 201761760000004976200000
Monday, January 1, 201860290000004572000000
Tuesday, January 1, 201962510000004444200000
Wednesday, January 1, 202057780000003796700000
Friday, January 1, 202160400000005575500000
Saturday, January 1, 202257600000006497000000
Sunday, January 1, 202361980000006438600000
Loading chart...

Unleashing the power of data

Gross Profit Trends: Viatris Inc. vs. Bausch Health Companies Inc.

In the ever-evolving pharmaceutical industry, understanding financial health is crucial. This analysis compares the gross profit trends of Viatris Inc. and Bausch Health Companies Inc. from 2014 to 2023. Over this period, Bausch Health's gross profit peaked in 2015, showing a 31% increase from 2014, before experiencing fluctuations. Meanwhile, Viatris Inc. demonstrated a steady upward trajectory, culminating in a 77% rise by 2022 compared to its 2014 figures. Notably, in 2022, Viatris surpassed Bausch Health, marking a significant shift in market dynamics. This trend continued into 2023, with Viatris maintaining a slight edge. These insights highlight the competitive landscape and strategic shifts within the sector, offering a glimpse into the financial strategies of these pharmaceutical giants. As the industry faces new challenges, these trends provide a valuable perspective on corporate resilience and adaptability.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025